Physician profile
Ryan K James
NPI 1669978276
$7,275.72
in general payments reported to CMS, 2019-2025
23 companies · $2,420 in 2025
The $2,420 reported for 2025 was more than what 79% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $410 · 2023: $448 · 2024: $3,998 · 2025: $2,420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,564 · Food and Beverage: $1,704 · Education: $1,597.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,564.15 |
| Food and Beverage | $1,704.07 |
| Education | $1,597.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,756.22 | 2024-2025 | |
| Steris Corporation | $2,675.78 | 2024 | |
| Medtronic, INC. | $858.32 | 2022-2023 | Illumisite |
| Erbe USA INC | $160.32 | 2025 | Vio/Cryo/Apc |
| Becton, Dickinson and Company | $149.99 | 2024 | Hemosphere |
| Galvanize Therapeutics, INC | $121.24 | 2025 | Aliya System |
| Regeneron Healthcare Solutions, INC. | $94.38 | 2025 | Dupixent |
| Grifols USA, LLC | $63.83 | 2025 | Prolastin-C Liquid |
| Astellas Pharma US INC | $59.91 | 2024 | Veozah |
| Olympus America INC. | $59.05 | 2024 | Single-Use Flexible Video Bronchoscope |
| Genzyme Corporation | $34.25 | 2025 | |
| Glaxosmithkline, LLC. | $29.18 | 2025 | Nucala, Trelegy Ellipta |
| Janssen Biotech, INC. | $28.23 | 2025 | Rybrevant |
| Pulmonx Corporation | $28.06 | 2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Pharmacosmos Therapeutics INC. | $23.33 | 2025 | Monoferric |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $22.23 | 2025 | Keytruda, Keytruda Qlex |
| Mallinckrodt Hospital Products INC. | $18.75 | 2025 | Acthar |
| Insmed, INC. | $17.38 | 2025 | Brinsupri |
| Astrazeneca Pharmaceuticals Lp | $16.23 | 2025 | Tezspire |
| Jazz Pharmaceuticals INC. | $16.11 | 2025 | |
| Electromed, INC. | $15.23 | 2025 | Smartvest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.66 | 2025 | |
| Ambu INC. | $13.04 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.